Department of Laboratory Medicine, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111, Szczecin, Poland.
Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University in Szczecin, Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland.
BMC Nephrol. 2020 Sep 11;21(1):394. doi: 10.1186/s12882-020-02053-8.
Platelet activation is an important side effect of dialysis, resulted in a subsequent release of arachidonic acid (AA) from activated platelets. AA is involved in many pathologic conditions, such as inflammation, asthma, cancer, diabetes, hypertension, and the pathogenesis of kidney disease. The aim of this study was to define whether the dialysis type affects the concentration of AA derivatives in patients with chronic kidney disease.
117 patients were qualified to the study group. Based on the type of renal replacement therapy, patients were divided into the following groups: hemodialysis (HD A - before/HD B - after hemodialysis), peritoneal dialysis (PD), kidney transplant patients (TE - before/TE A - after transplantation) and conservative treatment (CT) (30; 30; 27; 30 patients, respectively). The control group consisted of 30 healthy volunteers (NK). The ELISA methods were used to measure the concentrations of TXB2, 5-HETE, 12-HETE, and 15-HETE in the blood serum.
Renal replacement therapy significantly influences the concentration of TXB (mean ± SD [ng/mL]: HD A- 34.6 ± 9; HD B- 28.3 ± 15.2; PD- 28.3 ± 15.2; CT- 34.2 ± 8.0; TE- 36.7 ± 42.9; TE A- 27.9 ± 8.8; NK- 19.6 ± 15; p = 0.010), 5-HETE (mean ± SD [ng/mL]: HD A- 284.2 ± 428.4; HD B- 304.8 ± 516.2; PD - 530.0 ± 553.3; CT- 318.7 ± 366.0; TE- 525.6 ± 358.0; TE A - 409.8 ± 377.1; NK 838.1 ± 497.8; p < 0.001) and 15-HETE (HD A-18.1 ± 8.7; HD B- 42.2 ± 14; PD - 36.3 ± 13.8; CT- 33.7 ± 14.0; TE- 19.5 ± 10.2; TE A - 34.4 ± 16.3; NK 22.2 ± 17.8; p < 0,001). There was a significant relationship between the type of renal replacement therapy and the duration of dialysis, and the concentration of TXB, 12-HETE acid, and 15-HETE.
The type of renal replacement therapy significantly affects the concentration of AA derivatives. Peritoneal dialysis is the best method of dialysis, taking into account the concentration of arachidonic acid derivatives.
血小板激活是透析的一个重要副作用，导致随后从激活的血小板中释放花生四烯酸 (AA)。AA 参与许多病理状况，如炎症、哮喘、癌症、糖尿病、高血压和肾脏疾病的发病机制。本研究的目的是确定透析类型是否会影响慢性肾脏病患者 AA 衍生物的浓度。
将 117 名患者纳入研究组。根据肾脏替代治疗的类型，患者分为以下几组：血液透析（HD A-透析前/HD B-透析后）、腹膜透析（PD）、肾移植患者（TE-移植前/TE A-移植后）和保守治疗（CT）（分别为 30；30；27；30 名患者）。对照组由 30 名健康志愿者（NK）组成。采用 ELISA 法测定血清中 TXB2、5-HETE、12-HETE 和 15-HETE 的浓度。
肾脏替代疗法显著影响 TXB 的浓度（均值±SD[ng/mL]：HD A-34.6±9；HD B-28.3±15.2；PD-28.3±15.2；CT-34.2±8.0；TE-36.7±42.9；TE A-27.9±8.8；NK-19.6±15；p=0.010）、5-HETE（均值±SD[ng/mL]：HD A-284.2±428.4；HD B-304.8±516.2；PD-530.0±553.3；CT-318.7±366.0；TE-525.6±358.0；TE A-409.8±377.1；NK 838.1±497.8；p<0.001）和 15-HETE（HD A-18.1±8.7；HD B-42.2±14；PD-36.3±13.8；CT-33.7±14.0；TE-19.5±10.2；TE A-34.4±16.3；NK 22.2±17.8；p<0.001）。肾脏替代治疗的类型与透析时间之间存在显著关系，与 TXB、12-HETE 酸和 15-HETE 的浓度之间也存在显著关系。
肾脏替代治疗的类型显著影响 AA 衍生物的浓度。腹膜透析是考虑到花生四烯酸衍生物浓度的最佳透析方法。
